A role for the androgen receptor in the treatment of male breast cancer

Jason Zhu, Carter T. Davis, Sandra Silberman, Neil Spector, Tian Zhang

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Male breast cancer (BC) is relatively rare, making up less than 1% of all breast cancer cases in the United States. Treatment guidelines for male BC are derived from studies on the treatment of female BC, and are based molecular and clinical characteristics, such as hormone receptor positivity. For female estrogen receptor positive (ER+) breast cancers, the standard of care includes three classes of endocrine therapies: selective estrogen receptor modulators, aromatase inhibitors, and pure anti-estrogens. In contrast to female ER+ breast cancers, there is less known about the optimal treatment for male ER+ BC. Furthermore, in contrast to ER, less is known about the role of the androgen receptor (AR) in male and female BC. We report here the treatment of a 28-year-old man with metastatic AR+, ER+ breast cancer otherwise refractory to chemotherapy, who has had a durable clinical response to hormonal suppression with the combination of aromatase inhibition (Letrozole) in conjunction with a GnRH agonist (Leuprolide).

Original languageEnglish (US)
Pages (from-to)358-363
Number of pages6
JournalCritical Reviews in Oncology/Hematology
StatePublished - Feb 1 2016
Externally publishedYes


  • Androgen receptor
  • Breast cancer
  • Hormonal therapy
  • Male breast cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'A role for the androgen receptor in the treatment of male breast cancer'. Together they form a unique fingerprint.

Cite this